Kalaris Therapeutics officer reports initial holdings
Kalaris Therapeutics, Inc. officer Amy O'Leary Vandekop filed an initial statement of beneficial ownership.
Rhea-AI Filing Summary
Kalaris Therapeutics, Inc. officer Amy O'Leary Vandekop filed an initial statement of beneficial ownership. She reports direct ownership of 948 shares of common stock and two stock options over 27,415 shares at $7.31 expiring April 9, 2035 and 20,000 shares at $6.81 expiring March 18, 2036. Footnotes state the options were granted in April 2025 and March 2026, with 25% vesting on March 18, 2026 and March 19, 2027, respectively, and the remaining shares vesting in equal monthly installments through 2029 and 2030.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Vandekop Amy O'Leary
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) F1 | -- | -- | -- |
| holding | Stock Option (right to buy) F2 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 47,415 contracts (Direct);
Common Stock — 948 shares (Direct)
Footnotes (2)
- F1. The option was granted on April 10, 2025. The shares underlying the option vested with respect to 25% of the shares on March 18, 2026 and the remainder are scheduled to vest in equal monthly installments through March 18, 2029.
- F2. The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest with respect to 25% of the shares on March 19, 2027 and the remainder are scheduled to vest in equal monthly installments through March 19, 2030.
Key Figures
Common shares held: 948 shares
Option underlying shares 1: 27,415 shares
Exercise price 1: $7.31 per share
+4 more
7 metrics
Common shares held
948 shares
Directly owned common stock reported as of the Form 3 date
Option underlying shares 1
27,415 shares
Common stock underlying option at $7.31 exercise price, expiring April 9, 2035
Exercise price 1
$7.31 per share
Conversion or exercise price for 27,415-share stock option
Option underlying shares 2
20,000 shares
Common stock underlying option at $6.81 exercise price, expiring March 18, 2036
Exercise price 2
$6.81 per share
Conversion or exercise price for 20,000-share stock option
Vesting end date option 1
March 18, 2029
Monthly vesting of remaining shares after 25% vested March 18, 2026
Vesting end date option 2
March 19, 2030
Monthly vesting of remaining shares after 25% vests March 19, 2027
Key Terms
Stock Option (right to buy), beneficial ownership, vesting, Power of Attorney
4 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy) with underlying Common Stock"
beneficial ownership regulatory
"filed an initial statement of beneficial ownership"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
vesting financial
"shares underlying the option vested with respect to 25% of the shares"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Power of Attorney regulatory
"Exhibit 24.1 - Power of Attorney Associate VP, Corporate Controller"
A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the KLRS Form 3 filing by Amy O'Leary Vandekop report?
The Form 3 reports initial beneficial ownership for officer Amy O'Leary Vandekop, including 948 common shares held directly and two stock option awards over 27,415 and 20,000 shares of Kalaris Therapeutics common stock.
How many Kalaris Therapeutics (KLRS) options does Amy O'Leary Vandekop hold?
She holds two stock options covering 27,415 shares at $7.31 expiring April 9, 2035 and 20,000 shares at $6.81 expiring March 18, 2036, each for Kalaris Therapeutics common stock, all reported as directly owned.
What common stock position in KLRS is reported on this Form 3?
The filing lists a direct holding of 948 shares of common stock. This reflects the officer’s reported common equity stake separate from her stock options, which relate to additional underlying shares upon exercise.
What are the vesting schedules for the KLRS stock options reported?
For the 27,415-share option, 25% vested on March 18, 2026 and the rest vests monthly through March 18, 2029. For the 20,000-share option, 25% vests March 19, 2027 with remaining shares vesting monthly through March 19, 2030.
Did the KLRS Form 3 disclose any stock purchases or sales?
No buy or sell transactions are disclosed. The entries are reported as holdings, showing existing common stock and option positions, with zero buy and sell counts in the transaction summary.
AI-generated analysis. How Rhea-AI works. Not financial advice.
